# Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer

> **NCT07751055** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 51 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Ipilimumab (1mg/kg)
- **DRUG:** Sinitilimab
- **DRUG:** Nab-paclitaxel + Cisplatin
- **RADIATION:** IMRT combine with cisplatin concurrent chemotherapy

## Key facts

- **NCT ID:** NCT07751055
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751055, "Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07751055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*